Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.


Related Content

Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
Supreme Court Rejects Most Pharma Cases This Term, But Patent Settlements Stir Interest
Industry Roundup: J&J Supreme Court Petition, Ostroff Talks Supplement Regulation
Children's Motrin Label Ruling Shows 'Genuine Confusion' On Pre-emption – J&J
Another Motrin Failure-To-Warn Decision Rejects Pre-emption Defense
Decision For McNeil In Children's Motrin Suit Notes Limits Of OTC Labeling
High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst